by Naser AY. , Bilbisi M. , Mousa R. , Aburmilah A
Our model indicates that Isavuconazole is a cost-effective treatment option for IM in Jordan. Our findings can assist clinicians and healthcare decision-makers in prescribing cost-effective medications for patients with IM. Thus, healthcare resources will be utilized more efficiently.
Introduction: Invasive Aspergillosis (IA) and Mucormycosis (IM) continue to be life-threatening conditions associated with high rates of morbidity and mortality1. In Europe, the standard of care for the initial management of Mucormycosis is liposomal Amphotericin B (combined with surgical debridement). Isavuconazole, a new antifungal agent with a broader pathogen spectrum, demonstrated effectiveness in the management IM patients. Results The total cost for the treatment of IM was estimated to be 17,595.1 Jordanian Dinar (JOD) (one JOD equals 1.41 USD) for Isavuconazole and 109,001.8 JOD for liposomal amphotericin B. The estimated quality-adjusted life year (QALY) associated with Isavuconazole treatment for IM was 5.6088 QALY. The estimated QALY associated with liposomal amphotericin B treatment for IM was 4.92 QALY. Conclusions Our model indicates that Isavuconazole is a cost-effective treatment option for IM in Jordan. Our findings can assist clinicians and healthcare decision-makers in prescribing cost-effective medications for patients with IM. Thus, healthcare resources will be utilized more efficiently. References: 1. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported casesexternal icon. Clin Infect Dis. 2005 Sep 1;41(5):634-53. 2. Floros L, Kuessner D, Posthumus J, Bagshaw E, Sjölin J. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden. ; VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and casecontrol analysis. . Objectives :The aim of this study was to develop an economic model that examine the cost-effectiveness of Isavuconazole versus liposomal amphotericin B for the treatment of IM in Jordan. Method We conducted a cost-utility analysis comparing Isavuconazole (IV therapy for 15 days followed by 134 days oral therapy) and liposomal amphotericin B (IV therapy for 149 days) for the treatment of IM using a decision tree model.